ReviewOrphanet journal of rare diseases2014
Sneddon's syndrome: a comprehensive review of the literature.
Review in Orphanet journal of rare diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 91 citations in OpenAlex.
- Sneddon syndrome: one phenotype, distinct pathophysiological entities with tailored treatments.Science China. Life sciences · 2026Article
- Diffuse cerebral microhemorrhages in West Nile virus neuroinvasive disease: a case report.Journal of neurovirology · 2026Article
- A case series of Sneddon syndrome: clinical features, diagnostic workup, and literature review.BMC neurology · 2025Review
- Pediatric Sneddon syndrome presenting with early-onset liver fibrosis: a rare case report.Oxford medical case reports · 2025Article
- Central retinal artery occlusion as the initial manifestation of mixed connective tissue disease in a young woman: a case report.BMC ophthalmology · 2024Article
- Neurovascular Issues in Antiphospholipid Syndrome: Arterial Vasculopathy from Small to Large Vessels in a Neuroradiological Perspective.Journal of clinical medicine · 2024Review
- Sneddon Syndrome: A Case Report From Saudi Arabia.Cureus · 2024Article
- Recurrent Ischaemic Stroke Secondary to Cerebral Small Vessel Vasculopathy From Clonal B-Cell Lymphomatosis of Marginal Zone Origin.Case reports in neurological medicine · 2024Article
- Comprehensive insights of Sneddon syndrome: A clinical perspective.Journal of central nervous system disease · 2024Review
- Cognitive and psychiatric signs revealing Sneddon syndrome: A case report.Clinical case reports · 2023Article
- Article
- Advances in Management of the Stroke Etiology One-Percenters.Current neurology and neuroscience reports · 2023Review
- Sneddon syndrome: a rare cause of stroke hidden in plain sight.Acta neurologica Belgica · 2023Article
- Novel heterozygous COL4A2 variant c.2572A > G, p.(I858V) mimicking Sneddon's and Divry van Bogaert Syndrome.Journal of neurology · 2022Article
- The Relevance of Skin Biopsies in General Internal Medicine: Facts and Myths.Dermatology and therapy · 2022Review
- Heritable and non-heritable uncommon causes of stroke.Journal of neurology · 2021Review
- Sneddon syndrome: a comprehensive clinical review of 53 patients.Journal of neurology · 2021Article
- Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.Current neurology and neuroscience reports · 2021Review
- Characteristic imaging features of neurovascular involvement in primary Sneddon's syndrome: an analysis of 12 cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Concomitant myocardial injury and valvular disease in Sneddon syndrome: a case report.European heart journal. Case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sneddon's syndrome (SS) is a rare non-inflammatory thrombotic vasculopathy characterized by the combination of cerebrovascular disease with livedo racemosa(LR). The Orpha number for SS is ORPHA820. It has been estimated that the incidence of SS is 4 per 1 million per annum in general population and generally occurs in women between the ages of 20 and 42 years. LR may precede the onset of stroke by years and the trunk and/or buttocks are involved in nearly all patients. The cerebrovascular manifestations are mostly secondary to ischemia (transient ischemic attacks and cerebral infarct). Other neurological symptoms range from headache, cerebral hemorrhage, seizures, cognitive and psychiatric disturbances. The involved internal organs include heart, kidney, and eyes. Histological findings of skin are characteristic and the involved vessels are small to medium-sized arteries at the border of dermis to subcutis with a distinct histopathological time course. The main diagnostic criteria are general LR with typical histopathological findings on skin biopsy and focal neurological deficits. The pathogenesis is related to hypercoagulable state and intrinsic small-vessel vasculopathy. The optimal management remains an unsolved problem and long-term anticoagulation have been recommended for cerebral ischemic events based on the presumed pathogenesis. There are controversial results in treatment of SS with immunomodulatory agents. The aim of this review is to comprehensively discuss this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.